Advertisement
U.S. markets close in 4 hours 33 minutes

Lipigon Pharmaceuticals AB (publ) (9RP.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
0.0010-0.0002 (-16.67%)
As of 08:13AM CEST. Market open.
Currency in EUR

Valuation Measures4

Market Cap (intraday) 2.39M
Enterprise Value 684.16k
Trailing P/E 1.85
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)0.16
Price/Book (mrq)0.08
Enterprise Value/Revenue 0.84
Enterprise Value/EBITDA 0.00

Trading Information

Stock Price History

Beta (5Y Monthly) 0.43
52-Week Change 3-96.59%
S&P500 52-Week Change 339.07%
52 Week High 30.0454
52 Week Low 30.0001
50-Day Moving Average 30.0106
200-Day Moving Average 30.0155

Share Statistics

Avg Vol (3 month) 315
Avg Vol (10 day) 3100
Shares Outstanding 5148.33M
Implied Shares Outstanding 61.99B
Float 8128.78M
% Held by Insiders 124.61%
% Held by Institutions 18.21%
Shares Short 4N/A
Short Ratio 4N/A
Short % of Float 4N/A
Short % of Shares Outstanding 4N/A
Shares Short (prior month ) 4N/A

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Currency in SEK.

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Jun 30, 2024

Profitability

Profit Margin -217.19%
Operating Margin (ttm)-5.60%

Management Effectiveness

Return on Assets (ttm)-41.80%
Return on Equity (ttm)-76.68%

Income Statement

Revenue (ttm)9.33M
Revenue Per Share (ttm)0.09
Quarterly Revenue Growth (yoy)-44.10%
Gross Profit (ttm)N/A
EBITDA -21.85M
Net Income Avi to Common (ttm)-20.25M
Diluted EPS (ttm)-0.0200
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)19.48M
Total Cash Per Share (mrq)0.13
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)5.93
Book Value Per Share (mrq)0.17

Cash Flow Statement

Operating Cash Flow (ttm)-15.65M
Levered Free Cash Flow (ttm)-9.2M